다른 서비스와 비교했을 때 SRGA.Q 의 PS 비율은 어느 정도인가요?

SRGA.Q은 Price-To-Sales 비율(0x)을 기준으로 볼 때 동종 업계 평균(3.8x)과 비교했을 때 좋은 가치를 가지고 있습니다.

SRGA.Q 의 PS 비율은 US Medical Equipment 업계의 다른 회사와 어떻게 비교됩니까?

SRGA.Q 은 Price-To-Sales 0 US Medical Equipment 업계 평균( 3.3 x).

SRGA.Q 의 PS 비율과 공정 PS 비율은 어떻게 되나요? 회사의 예상 수익 성장률, 이익 마진 및 기타 위험 요소를 고려한 예상 PS 비율입니다.

평가 분석을 위한 SRGA.Q 의 Price-To-Sales 공정 비율을 계산하기에는 데이터가 부족합니다.

미래 현금 흐름을 볼 때 SRGA.Q 의 공정 가격은 얼마인가요? 이 추정에는 할인된 현금흐름 모델을 사용합니다.

평가 분석을 위해 SRGA.Q 의 공정 가치를 계산하기에는 데이터가 부족합니다.

애널리스트의 12개월 전망은 무엇이며 컨센서스 목표가에 대한 통계적 신뢰도가 있나요?

가격 예측을 표시하기에는 데이터가 부족합니다.

Surgalign Holdings (OTCPK:SRGA.Q) - 주가, 뉴스 및 분석

SRGA.Q 주식 개요

Surgalign Holdings, Inc., a medical technology company, develops, manufactures, distributes, and markets spinal hardware implants and biomaterial products worldwide. 자세한 내용

SRGA.Q 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	0/6
과거 실적	0/6
재무 상태	0/6
배당금	0/6

위험 분석

지난 5년간 매년 수익이 9.6% 씩 감소했습니다.

의미 있는 시가총액이 없습니다. ( $165K )

마이너스 주주 지분

최근 3개월간 주가 변동폭 심해

+ 2 더 많은 위험

Surgalign Holdings, Inc. 경쟁사

Procyon

OTCPK:PCYN

US$1.6m

InVitro International

OTCPK:IVRO

US$1.8m

Vycor Medical

OTCPK:VYCO

US$2.5m

Arch Therapeutics

OTCPK:ARTH

US$888.9k

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Surgalign Holdings
과거 주가
현재 주가	US$0.018
52주 최고치	US$4.00
52주 최저치	US$0.005
베타	1.49
11개월 변경	63.64%
3개월 변경 사항	-80.00%
1년 변경 사항	-99.50%
33년 변화	-99.97%
5년 변화	-99.99%
IPO 이후 변화	-100.00%

최근 뉴스 및 업데이트

Recent updates

Surgalign stock rises 7% after receiving FDA clearance of Cortera spinal fixation system

Aug 24

주주 수익률

	SRGA.Q	US Medical Equipment	US 마켓
7D	16.1%	1.5%	2.2%
1Y	-99.5%	20.8%	31.6%

수익률 대 산업: SRGA.Q 지난 1년 동안 20.8 %를 반환한 US Medical Equipment 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: SRGA.Q 지난 1년 동안 31.6 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is SRGA.Q's price volatile compared to industry and market?
SRGA.Q volatility
SRGA.Q Average Weekly Movement	40.5%
Medical Equipment Industry Average Movement	8.1%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

안정적인 주가: SRGA.Q 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: SRGA.Q 의 주간 변동성은 지난 1년 동안 28% 에서 40% 로 증가했습니다.

회사 소개

설립	직원	CEO	웹사이트
1997	240	Terry Rich	www.surgalign.com

Surgalign Holdings, Inc. 기본 사항 요약

Surgalign Holdings 의 수익과 매출은 시가총액과 어떻게 비교하나요?
SRGA.Q 기본 통계
시가총액	US$165.30k
수익(TTM)	-US$50.49m
수익(TTM)	US$78.12m

0.0x

P/S 비율

0.0x

P/E 비율

SRGA.Q 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
SRGA.Q 손익 계산서(TTM)
수익	US$78.12m
수익 비용	US$26.03m
총 이익	US$52.09m
기타 비용	US$102.58m
수익	-US$50.49m

최근 보고된 수익

Mar 31, 2023

다음 수익 날짜

n/a

주당 순이익(EPS)	-5.50
총 마진	66.68%
순이익 마진	-64.63%
부채/자본 비율	-54.1%

SRGA.Q 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

SRGA.Q 주식 개요

위험 분석

Surgalign Holdings, Inc. 경쟁사

OTCPK:PCYN

US$1.6m

OTCPK:IVRO

US$1.8m

OTCPK:VYCO

US$2.5m

OTCPK:ARTH

US$888.9k

가격 내역 및 성능

최근 뉴스 및 업데이트

Surgalign Holdings, Inc. Files Form 15

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million.

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA).

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from S&P TMI Index

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million.

Surgalign Holdings, Inc. Filed for Bankruptcy

Recent updates

Surgalign Holdings, Inc. Files Form 15

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) acquired NanOss Production Operations of RTI Surgical, Inc. for $2 million.

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) completed the acquisition of Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA).

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from S&P TMI Index

Xtant Medical Holdings, Inc. (NYSEAM:XTNT) entered into asset purchase agreement to acquire Certain assets from Surgalign Holdings, Inc. (NasdaqGS:SRGA) for $5 million.

Surgalign Holdings, Inc. Filed for Bankruptcy

Surgalign Holdings Receives Deficiency Letter from the Nasdaq Stock Market LLC Due to Non-Compliance with Minimum Market Value of Publicly Held Shares

Price target decreased by 19% to US$2.22

Consensus estimates of losses per share improve by 87%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Announces Release of HOLO AI Insights for Neurovascular Research

Surgalign Holdings, Inc. to Report Q1, 2023 Results on May 11, 2023

Consensus revenue estimates fall by 38%

Full year 2022 earnings: EPS misses analyst expectations

Surgalign Holdings, Inc. Announces 100th Case Completed Utilizing its Recently Launched Cortera™ Spinal Fixation System

Surgalign Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $11.99474 million.

Price target decreased to US$5.00

Consensus EPS estimates fall by 14%

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$11.00

Surgalign Holdings, Inc. Lowers Revenue Guidance for 2022

Surgalign Holdings, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Surgalign Holdings, Inc Launches Portfolio of Fortilink® with TiPlus™ Technology Products, Expanding its Addressable Market for Interbody Fusion Procedures

Surgalign Holdings, Inc. Announces Third Clinical Site in the Commercialization of Its Holo Portal™ Surgical Guidance System

Surgalign Announces FDA 510(K) Clearance of the Cortera Spinal Fixation System – the Company’s New Flagship Posterior Fixation Platform

Surgalign stock rises 7% after receiving FDA clearance of Cortera spinal fixation system

Surgalign Holdings Announces Asset Impairment for the Second Quarter Ended June 30, 2022

Surgalign revenue of $20.62M misses by $0.51M, reconfirms full-year revenue

Surgalign Holdings, Inc. Appoints Paolo Amoruso as New General Counsel and Corporate Secretary

Surgalign Holdings, Inc. Reaches Settlement with the Securities and Exchange Commission

Surgalign Holdings, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Surgalign Holdings, Inc. Announces Clinical Site Expansion in the Commercialization of Its HOLO Portal Surgical Guidance System in Ohio

Chief Financial Officer recently bought US$100k worth of stock

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Revises Revenue Guidance for the Fiscal Year 2022

Surgalign™ Announces the First Successful Surgical Procedure Utilizing Its HOLO Portal™ Surgical Guidance System

Price target decreased to US$1.00

Surgalign Holdings, Inc., Annual General Meeting, May 10, 2022

Joshua H. Derienzis Notifies Surgalign Holdings, Inc. of His Decision to Resign from His Position as Chief Legal Officer and Corporate Secretary, Effective May 10, 2022

Consensus forecasts updated

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Surgalign Holdings, Inc. Appoints David Lyle as Chief Financial Officer

Surgalign Holdings, Inc. Receives FDA Clearance for HOLO Portal™ System

Surgalign Holdings - A Future Of Digital Surgery

Price target decreased to US$2.85

Third quarter 2021 earnings released: US$0.06 loss per share (vs US$0.36 loss in 3Q 2020)

Sizing Up Surgalign

Independent Director Jeffrey Lightcap has left the company

Chairman Stuart Simpson has left the company

Surgalign Holdings: Insiders Are Buying

Surgalign Holdings, Inc. Announces Issuance of U.S. Patent Covering the Use of Artificial Intelligence in Medical Image Segmentation

President recently bought US$1.0m worth of stock

Surgalign Holdings: Pinocchio Has A Happy Ending

Second quarter 2021 earnings released: US$0.086 loss per share (vs US$0.30 loss in 2Q 2020)

Price target decreased to US$4.21

Surgalign Holdings: A Marketing Ploy

Surgalign Holdings, Inc.(NasdaqGS:SRGA) dropped from Russell 3000E Value Index

Surgalign reports inducement grants under Nasdaq listing rule

First quarter 2021 earnings released: US$0.15 loss per share (vs US$0.24 loss in 1Q 2020)

Surgalign Spine Technologies Submits Premarket Notification 510(K) of Its Digital Surgical Guidance System